Registered title, quoted from ClinicalTrials.gov
Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Nanjing Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07933952, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging and/or pathological examination.
Inclusion criterion 2
Pregnancy or breastfeeding.
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07933952, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged 18-80 years, regardless of sex.
- Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging and/or pathological examination.
- Meeting at least one of the following criteria:
- Liver metastasis from PDAC confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) at initial diagnosis or during the disease course.
- No evidence of liver metastasis at initial diagnosis, followed by curative-intent surgical resection and planned postoperative surveillance for liver metastasis.
- Availability of sufficient clinical information, including demographic characteristics, medical history, imaging and/or pathological findings, treatment information, liver metastasis status, and follow-up outcomes.
- Availability of a unique study identification code to ensure patient traceability and data linkage.
- For prospective enrollment and biospecimen collection, voluntary provision of written informed consent by the patient or their legally authorized representative, as required by the approved study protocol.
Exclusion Criteria:
- Concomitant diagnosis of other malignant tumors.
- Receipt of preoperative systemic antitumor therapy (neoadjuvant therapy) before curative-intent surgical resection, for patients in the resection subgroup.
- Severe cardiac, pulmonary, hepatic, or renal dysfunction.
- Active infectious diseases.
- Pregnancy or breastfeeding.
- Severe coagulation disorders, contraindications to blood collection, or an unacceptably high risk associated with blood collection as assessed by the investigator.
Quoted from ClinicalTrials.gov, NCT07933952, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07933952, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.